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Background: A remarkable correspondence exists between the cytogenetic locations of the known fragile sites
and frequently reported sites of hypermethylation. The best-known features of fragile sites are sequence motifs that
are prone to the spontaneous formation of a non-B DNA structure. These facts, coupled with the known
enzymological specificities of DNA methyltransferase 1 (DNMT1), the ATP-dependent and actin-dependent helicases,
and the ten-eleven translocation (TET) dioxygenases, suggest that these enzymes are involved in an epigenetic
cycle that maintains the unmethylated state at these sites by resolving non-B structure, preventing both the
sequestration of DNA methyltransferases (DNMTs) and hypermethylation in normal cells.
Presentation of the hypothesis: The innate tendency of DNA sequences present at fragile sites to form non-B
DNA structures results in de novo methylation of DNA at these sites that is held in check in normal cells by the
action of ATP-dependent and actin-dependent helicases coupled with the action of TET dioxygenases. This
constitutes a previously unrecognized epigenetic repair cycle in which spontaneously forming non-B DNA
structures formed at fragile sites are methylated by DNMTs as they are removed by the action of ATP-dependent
and actin-dependent helicases, with the resulting nascent methylation rendered non-transmissible by TET
dioxygenases.
Testing the hypothesis: A strong prediction of the hypothesis is that knockdown of ATP-dependent and
actin-dependent helicases will result in enhanced bisulfite sensitivity and hypermethylation at non-B structures
in multiple fragile sites coupled with global hypomethylation.
Implications of the hypothesis: A key implication of the hypothesis is that helicases, like the lymphoid-specific
helicase and alpha thalassemia/mental retardation syndrome X-linked helicase, passively promote accurate
maintenance of DNA methylation by preventing the sequestration of DNMTs at sites of unrepaired non-B DNA
structure. When helicase action is blocked due to mutation or downregulation of the respective genes, DNMTs
stall at unrepaired non-B structures in fragile sites after methylating them and are unable to methylate other
sites in the genome, resulting in hypermethylation at non-B DNA-forming sites, along with hypomethylation
elsewhere.Background
Our recent work on the mechanism of action of 2’-
deoxyriboguanylurea (GuaUre-dR) [1], the primary break-
down product of 5-aza-2’-deoxycytidine (5azaC-dR) [2],
coupled with work from multiple laboratories, as well as
our own, on DNA methyltransferases (DNMTs) [3-8], the
substrate specificity, mechanism of action and biological
effects of helicases, such as the ERCC2, ATRX, HELLS
and RecQ family of helicases [9-15], and the ten-eleven
translocation (TET) dioxygenases [16-19], suggest that the
mechanism responsible for most of the hypermethylation
observed during carcinogenesis involves the breakdown ofCorrespondence: ssmith@coh.org
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reproduction in any medium, provided the oran epigenetic repair cycle that maintains the unmethylated
state at and near the common fragile sites.
The classic examples of epigenetic downregulation in
human cells and tissues are genes that are often silenced
and hypermethylated during tumorigenesis. As demon-
strated in Table 1, the vast majority of these genes reside
at cytogenetic locations that define well-known fragile
sites. This remarkable cytogenetic correspondence strongly
suggests that hypermethylation, epigenetic downregulation
and chromosomal fragility share common mechanistic fea-
tures. The best-known feature of fragile sites is the pres-
ence of a sequence motif that is prone to the spontaneous
formation of a non-B DNA structure. In addition to
FRAXA [14], many other fragile sites have been shown tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Hypermethylation at known fragile sites
Gene Gene location Fragile site Fragile site type Fragile site location Methylation reference
RUNX3 1p36 FRA1A Aph, C 1p36 [24]
- - FRA1B Aph, C 1p32 -
ARHI 1p31 FRA1C Aph, C 1p31.2 [25]
PARG1 1p22.1 FRA1D Aph, C 1p22 [26]
- - FRA1E Aph, C 1p21.2 -
S100A6 1q21 FRA1F Aph, C 1q21 [27]
- - FRA1G Aph, C 1q25.1 -
PTGS2 1q25.2-25.3 FRA1G Aph, C 1q25.1 [28,29]
DISC1 1q42.1 FRA1H 5azaC-R, C 1q42 [30]
- - FRA1I Aph, C 1q44 -
- - FRA1J 5azaC-R, C 1q12 -
GLUL 1q31 FRA1K Aph, C 1q31 [31]
CLCA2 1p31 FRA1L Aph, C 1p31 [32]
MIR137 1p21.3 FRA1M Fol, R 1p21.3 [33]
- - FRA2A Fol, R 2q11.2 -
BCL2L11 2q13 FRA2B Fol, R 2q13 [34]
- - FRA2C Aph, C 2p24.2 -
MSH6 2p16 FRA2D Aph, C 2p16.2 [35]
DOK1 2p13 FRA2E Aph, C 2p13 [36]
RASSF1 3p21.3 - - - [37]
MLH1 3p21.3 - - - [38]
VHL 3p25.3 - - - [39]
LRP1B 2q21.2 FRA2F Aph, C 2q21.3 [40]
HOXD1 2q31.1 FRA2G Aph, C 2q31 [41]
- - FRA2H Aph, C 2q32.1 -
FLIP 2q33-q34 FRA2I Aph, C 2q33 [42]
KIF1A 2q37.3 FRA2J Aph, C 2q37.3 [43]
ZEB2 2q22.3 FRA2K Fol, R 2q22.3 [44]
RARβ 3p24.2 FRA3A Aph, C 3p24.2 [45]
FHIT 3p14.2 FRA3B Aph, C 3p14.2 [46]
- - FRA3C Aph, C 3q27 -
RARRES1 3q25.32 FRA3D Aph, C 3q25 [47]
PTX3 3q25 FRA3D Aph, C 3q25 [48]
- - FRA4A Aph, C 4p16.1 -
PDGFRA 4q12 FRA4B BrdU, C 4q12 [49]
SFRP2 4q31.3 FRA4C Aph, C 4q31.1 [50]
SLIT2 4p15.2 FRA4D Aph, C 4p15 [51]
- - FRA5A BrdU, C 5p13 -
- - FRA5B BrdU, C 5q15 -
NR3C1 5q31.3 FRA5C Aph, C 5q31.1 [52]
GPR150 5q15 FRA5D Aph, C 5q15 [53]
- - FRA5E Aph, C 5p14 -
APC 5q21-22 FRA5F Aph, C 5q21 [54]
- - FRA5G Fol, R 5q35 -
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SCGB3A1 5q35.3 FRA5G Fol, R 5q35 [55,56]
- - FRA6A Fol, R 6p23 -
- - FRA6B Aph, C 6p25.1 -
- - FRA6C Aph, C 6p22.2 -
- - FRA6C Aph, C 6p22.2 -
- - FRA6D BrdU, C 6q13 -
ESR1 6q25.1 - - - [57]
- FRA6E Aph, C 6q26 -
HACE1 6q21 FRA6F Aph, C 6q21 [58]
- - FRA6G Aph, C 6q15 -
- - FRA7A Fol, R 7p11.2 -
TWIST1 7p21.2 - - - [56]
- - FRA7B Aph, C 7p22
- - FRA7C Aph, C 7p14.2 -
IGFBP3 7p13-p12 FRA7D Aph, C 7p13 [59]
HIC1 17p13.3 FRA7D Aph, C 7p13 [60]
ABCB1 7q21.12 FRA7E Aph, C 7q21.2 [61]
TFPI2 7q22 FRA7F Aph, C 7q22 [62]
TES 7q31.2 FRA7G Aph, C 7q31.2 [63]
CFTR 7q31.2 FRA7G Aph, C 7q31.2 [64]
- - FRA7H Aph, C 7q32.3 -
EN2 7q36 FRA7I Aph, C 7q36 [65]
HSPB1 7q11.23 FRA7J Aph, C 7q11 [66]
- - FRA8A Fol, R 8q22.3 -
- - FRA8B Aph, C 8q22.1 -
MYC 8q24.21 FRA8C, Aph, C 8q24.1 [67]
- - FRA8D Aph, C 8q24.3 -
MYC 8q24.21 FRA8E Dmy, R 8q24.1 [67]
CDKN2A 9p21 FRA9A, Fol, R 9p21 [68]
CDKN2B 9p21 FRA9A, Fol, R 9p21 [69]
BRINP1 9q32-q33 FRA9B, Fol, R 9q32 [70]
CDKN2A 9p21 FRA9C, BrdU, R 9p21 [68]
CDKN2B 9p21 FRA9C, BrdU, R 9p21 [69]
DAPK1 9q21.33 FRA9D Aph, C 9q22.1 [71]
FRA9B, Aph, C 9q32
BARX1 9q12 FRA9F 5azaC-R, C 9q12 [72]
FRA10AC1 10q23.33 FRA10A Fol, R 10q23.3 [73]
PTEN 10q23.3 FRA10A Fol, R 10q23.3 [74]
- FRA10B BrdU, R 10q25.2
FRA10C BrdU, R 10q21
EGR2 10q21.1 FRA10D Aph, C 10q21.1 [75]
TYSND1 10q22.1 FRA10D Aph, C 10q22.1 [76]
- - FRA10E Aph, C 10q25.2
MGMT 10q26 FRA10F Aph, C 10q26.1 [77]
Table 1 Hypermethylation at known fragile sites (Continued)
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RET 10q11.2 FRA10G Aph, C 10q11.2 [78]
MRPL48 11q13.4 FRA11A Fol, R 11q13.3 [79]
AMICA1 11q23.3 FRA11B Fol, R 11q23.3 [80]
CALCB 11p15.2- FRA11C Aph, C 11p15.1 [81]
HRAS 11p15.5 FRA11C, Aph, C 11p15.1 [81]
MYOD1 11p15.4 FRA11C, Aph, C 11p15.1 [64]
- - FRA11D Aph, C 11p14.2
WT1 11p13 FRA11E Aph, C 11p13 [82]
CD44 11p13 FRA11E Aph, C 11p13 [83]
- - FRA11F Aph, C 11p14.2
PGR 11q22-q23 FRA11G Aph, C 11q23.3 [84]
GSTP1 11q13 FRA11H Aph, C 11q13 [85]
CCND2 12p13 - - - [56]
CALCB 11p15.2-15.1 FRA11I Aph, C 11p15.1 [81]
HRAS 11p15.5 FRA11I, Aph, C 11p15.1 [81]
MYOD1 11p15.4 FRA11I, Aph, C 11p15.1 [64]
- - FRA12A Fol, R 12q13.1
SLC6A15 12q21.3 FRA12B Aph, C 12q21.3 [62]
CHFR 12q24.33 FRA12C BrdU, R 12q24.2 [86]
- - FRA12D Fol, R 12q24.13
SELPLG 12q24 FRA12E Aph, C 12q24 [87]
BRCA2 13q12.3 FRA13A Aph, C 13q13.2 [35]
RB1 13q14.2 - - - [88]
PCDH20 13q21.2 FRA13B BrdU, C 13q21 [89]
PCDH20 13q21.2 FRA13C Aph, C 13q21.2 [89]
ZIC2 13q32 FRA13D Aph, C 13q32 [90]
- - FRA15A Aph, C 15q22
ABCC6 16p13.1 FRA16A Fol, R 16p13.11 [64]
CDH1 16q22.1 FRA16B, Dmy, R 16q22.1 [91]
CDH1 16q22.1 FRA16C Aph, C 16q22.1 [91]
CDH13 16q23.3 FRA16D Aph, C 16q23.2 [92]
WWOX 16q23.3-q24.1 FRA16D Aph, C 16q23.2 [93]
HIC1 17p13.3 - - - [60]
- - FRA17A Dmy, R 17p12
BRCA1 17q21.31 - - - [94]
SOX9 17q23 FRA17B Aph, C 17q23.1 [95]
CDH2 18q12.1 FRA18A Aph, C 18q12.2 [72]
SERPINB5 18q21.33 FRA18B Aph, C 18q21.3 [96]
BCL2 18q21.3 FRA18B Aph, C 18q21.3 [64]
- - FRA18C Aph, C 18q22.2
- - FRA19A 5azaC-R, C 19q13
- - FRA19B Fol, R 19p13
- - FRA20A Fol, R 20p11.23
- - FRA20B Aph, C 20p12.2
Table 1 Hypermethylation at known fragile sites (Continued)
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- - FRA20B Aph, C 20p12.2
FBLN1 22q13 FRA22A Fol, R 22q13 [97]
- 22q12.1 FRA22B Aph, C 22q12.2
AR Xq12 - - - [98]
FMR1 Xq27.3 FRAXA Fol, R Xq27.3 [14]
VCX Xp22 FRAXB Aph, C Xp22.31 [99]
VCX Xp22 FRAXC Aph, C Xq22.1 [99]
FMR1 Xq27.3 FRAXD Aph, C Xq27.2 [100]
FMR2 Xq28 FRAXE, Fol, R Xq28 [101]
FMR2 Xq28 FRAXF Fol, R Xq28 [101]
Definitions for standard gene abbreviations are available at the HUGO Gene Nomenclature Committee (HGNC) website [102]. Aph, aphidicolin; 5azaC-R,
5-azacytidine ; BrdU, bromodeoxyuridine; C, common; Dmy, distamycin; Fol, folate; R, rare.
Table 1 Hypermethylation at known fragile sites (Continued)
Smith Clinical Epigenetics 2013, 5:17 Page 5 of 10
http://www.clinicalepigeneticsjournal.com/content/5/1/17harbor sequences, such as the CCG triplet repeat, which
form hairpins, slippage intermediates (Figure 1A) and
quadruplex structures. Non-B intermediates are known to
be exceptional substrates for de novo methylation by DNA
methyltransferase 1 (DNMT1) [6,7,20] either at its three-
nucleotide recognition motif (Figure 1) within the repeat
if it contains CG sites or at the same motif at CG sites
flanking the non-B sequence if it does not. Consequently,
even fragile sites that contain AT-rich sequences with high
torsional flexibility and the potential for non-B DNA
structure formation are subject to methylation in regions
flanking the repeat. Other fragile sites that lack CG di-
mers, such as the Huntington’s disease CAG repeat, which
can also form hairpins and slippage intermediates [7,21],
appear to induce methylation at the flanking and other
regions where CG dimers occur [7,22]; for a review, see
Lukusa and Fryns [23].
Presentation of the hypothesis
The key components of the hypothesis, presented in Figure
1, are: 1) carcinogenesis-linked hypermethylation that oc-
curs primarily at or near fragile sites as a result of the ten-
dency of DNA sequences at these sites to form non-B
structures; 2) methylation is applied de novo to these struc-
tures and their neighboring sequences not only by
DNMT3A/3B but also by DNMT1; 3) during normal repli-
cation methylated non-B DNA structures are returned to
the B form by ERCC2, ATRX, HELLS and RecQ helicases;
4) sequences that cannot be resolved by helicase action are
removed by excision; 5) hydroxymethylation applied to the
nascent methyl groups by the action of TET dioxygenases
prevents sequences that are resolved by helicase action
from undergoing maintenance methylation by DNMT1,
regenerating the unmethylated state at these sites in normal
cells (in this regard, it is important to recognize that reso-
lution of these structures will result in hemimethylated
DNA, and that hemimethylated DNA is the preferredsubstrate of TET1 dioxygenase [17]); and 6) in addition to
DNA damage, carcinogenesis-linked dysfunction among
the helicases results in hypermethylation at and near fragile
sites, and hypomethylation elsewhere.Testing the hypothesis
While the existing evidence for the proposed cycle is com-
pelling, currently available experimental approaches per-
mit several additional tests of the hypothesis. For example,
transient knockdown by transfection-mediated expression
of an ERCC2, ATRX, HELLS or RecQ helicase is predicted
to result in a transient hypermethylation, coupled with an
increase in local hydroxymethylation content at affected
fragile sites. Stable knockdown is expected to result in
both hypermethylation at affected fragile sites and global
hypomethylation. In particular, the knockdown of the
WRN helicase (REQL2) is predicted to result in hyper-
methylation of the FHIT gene at FRA3B [108], coupled
with enhanced bisulfite sensitivity [109] of native DNA as-
sociated with the increased presence of non-B DNA struc-
ture at this site [109,110]. Existing studies on the effect of
WRN mutations on methylation, for example, do not ad-
dress early events at fragile sites, since they use cell lines that
have been carried in culture or were isolated from adults
bearing the WRN mutation [111,112]. Chromatin immuno-
precipitation with antibodies to DNMT1 is expected to yield
DNA that is enriched for fragile site sequences after helicase
knockdown. Determining the levels of DNMT1 by immuno-
blotting after helicase knockdown would determine whether
or not the removal of stalled DNMT1 involves proteolysis
[113]. WRN knockdown coupled with DNMT1 knock-
down is expected to produce enhanced bisulfite sensitivity
[109,110] in the absence of hypermethylation, while en-
hanced bisulfite sensitivity after knockdown of DNMT1
alone would provide evidence for an obligatory role of
methylation in non-B structure resolution.
Figure 1 Key systems maintaining the active and unmethylated state of DNA at sequences with the innate potential for non-B DNA
structure formation. In this enzymologically-based model, non-B DNA structure forms spontaneously or in response to replication stress or
carcinogen-linked damage, inducing DNA methylation de novo [3,4,103,104]. The three-nucleotide recognition motif [4] of DNMT1 (C:G-C) is
highlighted in the schematic of the non-B structure in the upper right of the figure. Helicase resolution at non-B structures produces
hemimethylated DNA. Hypermethylation is prevented by the action of TET dioxygenase on its preferred hemimethylated substrate [17]. When
stress overwhelms the capacity of TET dioxygenase to hydroxymethylate hemimethylated DNA in the affected region, hypermethylation will
result. In this model, helicase lesions, DNMT lesions or TET dioxygenase lesions are expected to generate chromosome instability and the
selective induction of fragile sites. Methylated unusual DNA structures that are not resolved by helicase action may be removed by excision
repair-linked pathways where the unmethylated state is restored by DNA synthesis. (A) Molecular model of the hypermethylated C-rich strand
hairpin formed at fragile site FRAXA. The model was constructed in Biograf 3.1 (Molecular Simulations Inc, San Diego, CA, USA) and rendered with
the UCSF Chimera package (Resource for Biocomputing, Visualization, and Informatics, University of California, San Francisco, CA, USA). It is based
on NMR data presented by Chen et al. [20]. (B) Activity of human DNA methyltransferase 1 (hDNMT1) on hemimethylated DNA and
hemihydroxymethylated DNA. hDNMT1 was purified from nuclear extracts [105] prepared from cultured HeLa S3 cells. Purification and enzyme
activity measurements were carried out as previously described [106,107]. The purified enzyme had a specific activity of 20.96 fmole3HCH3/min/
mg. Duplex ODN substrates were synthesized and annealed as previously described [107]. The results confirm the findings of Hashimoto et al.
[17] with cloned DNMT1.
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overexpression of TET dioxygenases is expected to reduce
de novo methylation at fragile sites caused by helicase
knockdown, and knockdown of the dioxygenases should
enhance de novo methylation at these same sites.
Implications of the hypothesis
The hypothesis is consistent with other suggestions for
the genesis of hypermethylation [114,115]. Disruptions
in the histone code might be expected to elicit fragile
site formation, since exposure to carcinogens thatdamage DNA or block the histone modification pro-
cesses, may also induce fragile sites. Alterations in DNA
structure induced by miRNA (possibly via R-loop forma-
tion) could have similar effects at these sites. Moreover,
the remarkable correspondence between sites of
reported hypermethylation and fragile sites suggests that
the mutational and epimutational base upon which na-
tural selection can act during carcinogenesis is largely
confined to these sites. Their tendency to adopt non-B
DNA structures provides a compelling case for how they
become available for natural selection.
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genetic, DNA methylation and enzymological evidence. En-
zymological and biological evidence from our laboratory
suggests that DNMTs have evolved to recognize non-B
DNA structures, like those associated with FRAXA in fra-
gile X-linked mental retardation, and FRA11I/FRA11C in
breast and prostate cancer [20,107,110], suggesting that
DNMTs play an obligate role in the suppression of non-B
DNA structures [116,117] along with associated repair sys-
tems. Given an obligate role for DNMTs in the suppression
of non-B structure formation, the role of helicases in the
process can be better understood. In general, deficiencies in
helicases, such as ATRX, HELLS, BLM and WRN, have
been shown to result in either global genomic demethyla-
tion [118,119], gene activation [10], or both global deme-
thylation and gene activation. Two diametrically opposed
interpretations of normal function of these helicases have
been proposed. In one interpretation, they are viewed as ac-
tively promoting DNA methylation [118,120]. In the alter-
native interpretation, they are viewed as passively promoting
normal DNA methylation by preventing the sequestration
of DNMTs [107,117] at unresolved non-B structures [10].
The enzymological evidence supports the alternative inter-
pretation. For example, the WRN helicase has been shown
to resolve quadruplex DNA [15] and deficiency appears to
result in the accumulation of non-B structures [10]. The evi-
dence suggests that the DNMTs remain bound to non-B
DNA sequences containing mispaired cytosines [107], oxi-
dized bases [121] or DNA containing base analogs, such as
deoxyuridine (dU) [122], 5azaC-dR or GuaUre-dR [1]. It fol-
lows, that in cases of helicase deficiency, DNMT sequestra-
tion at a site of hypermethylation will result in global
hypomethylation, much like the effects of 5-azacytidine
(5azaC-R), 5azaC-dR and GuaUre-dR result in hypo-
methylation, since tightly bound DNMTs are unable to
maintain normal methylation patterns. Moreover, this model
(Figure 1) and the postulated obligatory role for DNMTs
suggests that the cytogenetic overlap between 5azaC-R,
5azaC-dR and GuaUre-dR-induced fragile sites FRA1J and
FRA9F, and the undercondensations observed in DNMT3B
mutants [123] and knockouts [124], is the result of the
complete titration of DNMT3B by non-B structures that re-
main unresolved and unrepaired after exposure to these
compounds. The selective effect on DNMT3B as opposed
to DNMT1 can be attributed to its low level of expression
relative to DNMT1. Estimates from purification data [107]
suggest that DNMT1 levels are in the order of several thou-
sand copies per cell. Northern blotting suggests that the
abundance of DNMT3B is ten to twentyfold below that of
DNMT1 at a few hundred copies per cell [125]. The DNA
footprint of DNMT1 is approximately 23 bp [126]. Thus, a
single non-B structure involving even 1,000 bases of single-
stranded DNA could sequester approximately 2% of the
DNMT1 or 20% of the DNMT3B. Replication stress-inducing agents, such as aphidicolin or distamycin, can be
expected to induce multiple non-B regions. During carcino-
genesis, multiple rounds of sequential induction of fragile
sites by replication stress and carcinogen action could
result in global hypomethylation. Moreover, the shattering
of metaphase that occurs at high concentrations of 5-aza-
CR contrasted with the confined induction of fragile sites
at low concentration [127] is consistent with the idea that
DNMT3B is knocked out at low concentration and
DNMT1 at higher concentration, and that both are obliga-
torily involved in suppressing fragile sites. Finally, work
with the TET dioxygenases [16-19] and the response of
DNMTs to 5-hydroxymethylcytosine (hmC) strongly sug-
gest that hydroxymethylation at repaired and methylated
genes in fragile sites will act to restore the unmethylated
active state of these genes (Figure 1B).
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